{
    "clinical_study": {
        "@rank": "28272", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1: Treatment A-B-C", 
                "arm_group_type": "Experimental", 
                "description": "The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days."
            }, 
            {
                "arm_group_label": "Sequence 2: Treatment B-C-A", 
                "arm_group_type": "Experimental", 
                "description": "The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days."
            }, 
            {
                "arm_group_label": "Sequence 3: Treatment C-A-B", 
                "arm_group_type": "Experimental", 
                "description": "The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics (what the body does to the\n      medication) and pharmacodynamics (the action of the medication on the body) of JNJ-28431754\n      (canagliflozin) and its main metabolites (break-down products) following 2 different doses\n      of canagliflozin in healthy Chinese volunteers. Safety and tolerability of canagliflozin\n      will also be assessed."
        }, 
        "brief_title": "A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study will be a double-blind (neither the Investigator nor volunteer knows the assigned\n      treatment), randomized (the treatment is assigned by chance), placebo-controlled (one of the\n      study treatments is inactive), single-dose, 3-way cross over study (all volunteers will\n      receive each of the 3 treatments but in a different order) in healthy Chinese volunteers.\n      Volunteers will be assigned to 1 of 3 treatment sequence groups (ABC, BCA, or CAB). The\n      treatment sequence will be decided by randomization. Treatment A will be a single oral (by\n      mouth) dose of 100 mg of canagliflozin. Treatment B will be a single oral dose of 300 mg of\n      canagliflozin.  Treatment C will be a single oral dose of placebo (inactive medication).\n      Each treatment will be given during a treatment period of 5 days duration; each treatment\n      period will be separated by a washout period (a time period with no medication) of at least\n      10 days. Canagliflozin is currently being investigated for the treatment of type 2 diabetes\n      mellitus (T2DM)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Volunteers must be non-smokers for at least 6 months before first study drug\n             administration\n\n          -  Volunteers must consume no more than 4 to 5 cups of coffee or tea or 8 cans of cola\n             each day\n\n        Exclusion Criteria:\n\n          -  History of or currently active illness considered to be clinically significant by the\n             Investigator or any other illness that the Investigator considers should exclude the\n             patient from the study or that could interfere with the interpretation of the study\n             results\n\n          -  Female volunteer is breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707316", 
            "org_study_id": "CR100923", 
            "secondary_id": "28431754DIA1026"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1: Treatment A-B-C", 
                    "Sequence 2: Treatment B-C-A", 
                    "Sequence 3: Treatment C-A-B"
                ], 
                "description": "Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.", 
                "intervention_name": "Treatment A: Canagliflozin 100 mg", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-28431754"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1: Treatment A-B-C", 
                    "Sequence 2: Treatment B-C-A", 
                    "Sequence 3: Treatment C-A-B"
                ], 
                "description": "Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.", 
                "intervention_name": "Treatment B: Canagliflozin 300 mg", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-28431754"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1: Treatment A-B-C", 
                    "Sequence 2: Treatment B-C-A", 
                    "Sequence 3: Treatment C-A-B"
                ], 
                "description": "Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.", 
                "intervention_name": "Treatment C: Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "JNJ-28431754", 
            "Canagliflozin", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "February 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of JNJ-28431754 (Canagliflozin) in Healthy Chinese Subjects", 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Plasma concentrations of canagliflozin and its major metabolites will be used to determine pharmacokinetic parameters (measurements that explore what the body does to the drug) for canagliflozin and its major metabolites.", 
                "measure": "Plasma concentrations of canagliflozin and its major metabolites following a single 100 mg and 300 mg dose", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 4"
            }, 
            {
                "description": "Urine concentrations of canagliflozin and its major metabolites will be used to determine pharmacokinetic parameters for canagliflozin and its major metabolites.", 
                "measure": "Urine concentrations of canagliflozin and its major metabolites following a single 100 mg and 300 mg dose", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707316"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Renal threshold is defined as the plasma glucose concentration above which glucose is excreted in the urine.", 
                "measure": "Renal threshold for glucose excretion following a single 100 mg dose of canagliflozin, 300 mg dose of canagliflozin, and placebo (inactive medication)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 2"
            }, 
            {
                "description": "UGE is equal to the amount of glucose excreted into the urine over defined time intervals.", 
                "measure": "Urine glucose excretion (UGE) following a single 100 mg dose of canagliflozin, 300 mg dose of canagliflozin, and placebo (inactive medication)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 2"
            }, 
            {
                "measure": "Mean plasma glucose concentration following a single 100 mg dose of canagliflozin, 300 mg dose of canagliflozin, and placebo (inactive medication)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 2"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}